What you need to know:
– Limbic, a London-based clinical mental health AI technology provider, has raised $14 million led by Khosla Ventures.
– The funding also includes participation from Gainels and Illusian and will accelerate Limbic’s expansion into the U.S. healthcare market.
Proven success in the UK, expansion to the US
Limbic’s clinical AI platform has already positively impacted more than 260,000 patients in the UK’s National Health Service (NHS) talk therapy program. This technology has been proven to:
– Increased access to mental health services
– Accelerate patient onboarding
– Reduced waiting time
– Improving quality of care
The newly secured funding will be used to expand the availability of Limbic’s AI solutions to U.S. healthcare providers. Initial partnerships with U.S. health systems and payers are expected to be announced in the coming months.
Correcting disparities and improving efficiency
Limbic’s technology has clearly increased access to mental health care, especially in underserved communities. A recent study in Nature Medicine found that his use of Limbic within the NHS resulted in:
– 179% increase in referrals between non-binary individuals
– 39% increase in Asian patient referrals
– 40% increase in Black patient referrals
Additionally, peer-reviewed studies have shown that Limbic’s platform has saved NHS clinicians more than 50,000 hours of time.
Beyond the clinical setting: supporting patients between sessions
Limbic offers the world’s first generative AI mental health companion, providing users with continuous support between treatment sessions. This chatbot interface leverages Limbic’s advanced AI to guide users through a variety of activities and educational materials, providing clinically rigorous mental health support on demand.
